OTC Markets OTCPK - Delayed Quote USD
Recce Pharmaceuticals Ltd (RECEF)
At close: October 16 at 4:00 PM EDT
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Operating Expense
22,051.2370
22,051.2370
17,242.5090
12,597.2540
15,199.8470
Operating Income
-22,051.2370
-22,051.2370
-17,242.5090
-12,597.2540
-15,199.8470
Net Non Operating Interest Income Expense
-659.8490
-659.8490
-117.0750
79.0720
93.6160
Other Income Expense
5,049.3720
5,049.3720
4,282.1620
1,531.9050
1,592.8650
Pretax Income
-17,661.7140
-17,661.7140
-13,077.4220
-10,986.2770
-13,513.3660
Net Income Common Stockholders
-17,661.7140
-17,661.7140
-13,077.4220
-10,986.2770
-13,513.3660
Basic EPS
-0.06
-0.10
-0.07
-0.06
-0.09
Diluted EPS
-0.06
-0.10
-0.07
-0.06
-0.09
Basic Average Shares
176,814.9760
177,099.7870
175,713.6130
175,870.5690
156,954.6430
Diluted Average Shares
176,814.9760
177,099.7870
175,713.6130
175,870.5690
156,954.6430
Net Income from Continuing & Discontinued Operation
-17,661.7140
-17,661.7140
-13,077.4220
-10,986.2770
-13,513.3660
Normalized Income
-17,661.7140
-17,661.7140
-13,077.4220
-10,986.2770
-13,513.3660
Interest Income
187.0030
187.0030
66.1900
90.9980
105.7570
Interest Expense
806.6140
806.6140
172.6230
2.4160
2.1070
Net Interest Income
-659.8490
-659.8490
-117.0750
79.0720
93.6160
EBIT
-16,855.1000
-16,855.1000
-12,904.7990
-10,983.8610
-13,511.2590
EBITDA
-16,488.3320
-16,488.3320
-12,687.6440
-10,796.1890
-13,215.6290
Reconciled Depreciation
366.7680
366.7680
217.1550
187.6720
295.6300
Net Income from Continuing Operation Net Minority Interest
-17,661.7140
-17,661.7140
-13,077.4220
-10,986.2770
-13,513.3660
Normalized EBITDA
-16,488.3320
-16,488.3320
-12,687.6440
-10,796.1890
-13,215.6290
6/30/2021 - 8/12/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade